UKINETS and the NET Patient Foundation have been involved as stakeholders and are providing input into the following reviews being undertaken by NICE:
Multiple Technology Appraisal (MTA) | Neuroendocrine tumours (metastatic, unresectable) – everolimus, lanreotide, lutetium-177 and sunitinib (after progression) [ID858]. Following a stakeholder meeting on 12 July 2017 this scope has been amended to “Everolimus, lutetium-177 DOTATATE and sunitinib for treating unresectable or metastatic neuroendocrine tumours with disease progression”, i.e. with the removal of lanreotide from this MTA. This is in keeping with lanreotide data published in the CLARINET study.
Next steps: the closing date for comments for the updated scope closed on 5th Aug 2016.
Expected publication date (NICE website): July 2017.
Single Technology Appraisal (STA) | Gastroenteropancreatic tumours (unresectable, metastatic, non-progressive) – lanreotide (subcutaneous injection) [ID961]. This STA is already underway; however, the scope may be amended given the removal of lanreotide from the MTA, as detailed above.
Expected publication date (NICE website): January 2017.